Sporadic Parkinson's Disease Program

About DaCapo Brainscience

DaCapo Brainscience is a private, preclinical-stage biotech founded in 2016 and based in Boston/Cambridge, MA. The company has built a proprietary, human biology-focused discovery platform designed to identify and validate novel targets linked to disease progression in neurodegenerative disorders. DaCapo has identified its first proprietary target for sporadic Parkinson's disease and is currently screening brain-penetrant small molecules, positioning it to address a significant unmet need in a large patient population. The company's work is supported by a grant from The Michael J. Fox Foundation.

Therapeutic Areas